Molecular mechanisms of insulin resistance and the role of the adipocyte

International Journal of Obesity

Volumn 24, Issue , 2000, Pages S23-S27

  Hotamisligil, G S ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Diabetes; Insulin receptor signaling; TNF ; Transgenic mice; Tumor necrosis factor

Indexed keywords

BETA 3 ADRENERGIC RECEPTOR; CYTOKINE; FATTY ACID BINDING PROTEIN; INSULIN; INSULIN RECEPTOR; LEPTIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; BROWN ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DISEASE PREDISPOSITION; DYSLIPIDEMIA; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC BALANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TEMPERATURE ACCLIMATIZATION; TRANSGENIC MOUSE;

ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; INSULIN RESISTANCE; MICE; MICE, TRANSGENIC; OBESITY; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; MUS MUSCULUS; RODENTIA;

EID: 0033694663     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0801497     Document Type: Article

References (41)

1. Moller DE, Flier JS. Insulin resistance: mechanisms, syndromes, and implications. New Engl J Med 1992; 325: 938-948.
2. Olefsky JM, Molina JM. Insulin resistance in man. In: Rifkin H, Porte DJ (eds). Diabetes Mellitus. Elsevier Science: New York, 1990, pp 121-153.
3. Katz EB, Stenbit AE, Hatton K, DePinho R, Charron MJ. Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in Glut4. Nature 1995; 377: 151-155.
4. Freidenberg GR, Henry RR, Klein HH, Reichart DR, Olefsky JM. Decreased kinase activity of insulin receptors from adipocytes of non-insulin-dependent diabetic subjects. J Clin Invest 1987; 79: 240-250.
5. Saad MJA, Araki E, Miralpeix M, Rothenberg PL, White MF, Kahn CR. Regulation of insulin receptor substrate-1 in liver and muscle of animal models of insulin resistance. J Clin Invest 1992; 90: 1839-1849.
6. Lauro D, Kido Y, Castle AL, Zarnowski MJ, Hayashi H, Ebina Y, Accili D. Impaired glucose tolerance in mice with a targeted impairment of insulin action in muscle and adipose tissue. Nature Genet 1998; 20: 294-298.
7. Bruning JC, Michael MD, Winnay JN, Hayashi T, Horsch D, Accili D, Goodyear LJ, Kahn CR. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol Cell 1998; 2: 559-569.
8. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR. Tissue-specific knockout of the insulin receptor in pancreatic ß cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 1999; 96: 329-339.
9. Spiegelman BM, Frank M, Green H. Molecular cloning of mRNA from 3T3 adipocytes. Regulation of mRNA content for glycerolphosphate dehydrogenase and other differentiation-dependent proteins during adipocyte development. J Biol Chem 1983; 258: 10083-10089.
10. Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996; 274: 1377-1379.
11. Coe NR, Simpsom MA, Bernlohr DA. Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. J Lipid Res 1999; 40: 967-972.
12. Scheja L, Makowski L, Uysal KT, Wiesbrock SW, Shimshek DR, Meyers DS, Morgan M, Parker RA, Hotamisligil GS. Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/-mice. Diabetes 1999; 48: 1987-1994.
13. Reynet C, Kahn CR. Rad: a member of the Ras family overexpressed in muscle of type II diabetic humans. Science 1993; 262: 1441-1444.
14. Maddux BA, Sbraccia P, Kumakura S, Sasson S, Youngren J, Fisher A, Spencer S, Grupe A, Henzel W, Stewart TA, Reaven GM, Goldfine ID. Membrane glycoprotein PC-1 and insulin resistance in non-insulin-dependent diabetes mellitus. Nature 1995; 373: 448-451.
15. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
16. Sethi JK, Hotamisligil GS. The role of TNFa in adipocyte metabolism. Semin Cell Devl Biol 1999; 10: 19-29.
17. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46: 3-10.
18. Hotamisligil GS, Spiegelman BM. TNF alpha and the insulin resistance of obesity. In: LeRoith D, Taylor SI, Olefsky JM (eds). Diabetes Mellitus, a Fundamental and Clinical Text. Lippincott-Raven: Philadelphia, 1996, pp 554-560.
19. Cheung AT, Ree D, Kolls JK, Coy DH, Bryer-Ash M. An in vivo model for elucidation of the mechanism of tumor necrosis factor-a (TNF-a)-induced insulin resistance: evidence for differential regulation of insulin signaling by TNF-a. Endocrinology 1998; 139: 4928-4935.
20. Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of TNFa by human muscle: relationship to insulin resistance. J Clin Invest 1996; 97: 1111-1116.
21. Perusse L, Chagnon YC, Weisnagel J, Bouchard C. The human obesity gene map: the 1998 update. Obes Res 1999; 7: 111-129.
22. Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R. Effects of an engineered human anti-TNF-a antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996; 45: 881-885.
23. Feinstein R, Kanety H, Papa MZ, Lunenfeld B, Karasik A. Tumor necrosis factor-a suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem 1993; 268: 26055-26058.
24. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 1994; 91: 4854-4858.
25. Hotamisligil GH, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-a-and obesity-induced insulin resistance. Science 1996; 271: 665-668.
26. Kroder G, Bossenmaier B, Kellerer M, Capp E, Stoyanov B, Muhlhofer A, Betin L, Horikoshi H, Ullrich A, Haring H. Tumor necrosis factor-alpha-and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signaling. J Clin Invest 1996; 97: 1471-1477.
27. Hotamisligil GS, Budavari A, Murray DL, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes: central role of tumor necrosis factor-a. J Clin Invest 1994; 94: 1543-1549.
28. Kanety H, Feinstein R, Papa MZ, Hemi R, Karasik A. Tumor necrosis factor alpha-induced phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-stimulated tyrosine phosphorylation of IRS-1. J Biol Chem 1995; 270: 23780-23784.
29. Peraldi P, Hotamisligil GS, Buurman WA, White MF, Spie-gelman BM. Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the P55 TNF receptor and activation of sphingomyelinase. J Biol Chem 1996; 271: 13018-13022.
30. Paz K, Hemi R, Leroith D, Karasik A, Elhanany E, Kanety H, Zick Y. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 1997; 272: 29911-29918.
31. Valverde AM, Teruel T, Navarro P, Benito M, Lorenzo M. Tumor necrosis factor-alpha causes insulin receptor substrate-2-mediated insulin resistance and inhibits insulin-induced adipogenesis in fetal brown adipocytes. Endocrinology 1998; 139: 1229-1288.
32. Kellerer M, Mushack J, Mischak H, Haring HU. Protein kinase C (PKC) epsilon enhances the inhibitory effect of TNF alpha on insulin signaling in HEK293 cells. FEBS Lett 1997; 418: 119-122.
33. Kellerer M, Mushack J, Seffer E, Mischak H, Ullrich A, Haring HU. Protein kinase C isoforms alpha, delta and theta require insulin receptor substrate-1 to inhibit the tyrosine kinase activity of the insulin receptor in human kidney embryonic cells (Hek293 Cells). Diabetologia 1998; 41: 833-838.
34. Kanety H, Hemi R, Papa MZ, Karasik A. Sphingomyelinase and ceramide suppress insulin-induced tyrosine phosphorylation of the insulin receptor substrate-1. J Biol Chem 1996; 271: 9895-9897.
35. Ahmad F, Goldstein BJ. Effect of tumor necrosis factor-alpha on the phosphorylation of tyrosine kinase receptors is associated with dynamic alterations in specific protein-tyrosine phosphatases. J Cell Biochem 1997; 64: 117-127.
36. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997; 389: 610-614.
37. Ventre J, Doebber T, Wu M, Macnaul K, Stevens K, Paspar-akis M, Kollias G, Moller DE. Targeted disruption of the tumor necrosis factor-alpha gene-metabolic consequences in obese and nonobese mice. Diabetes 1997; 46: 1526-1531.
38. Uysal KT, Wiesbrock SM, Hotamisligil GS. Functional ana-lysis of TNF receptors in TNF-alpha-mediated insulin resis-tance in genetic obesity. Endocrinology 1998; 139: 4832-4838.
39. Samad F, Uysal KT, Wiesbrock SM, Pandey M, Hotamisligil GS, Loskutoff DJ. Tumor necrosis factor a is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1. Proc Natl Acad Sci USA 1999; 96: 6902-6907.
40. Nisoli E, Briscini L, Tonello C, Wiesbrock SM, Uysal KT, Cinti S, Carruba MO, Hotamisligil GS. Tumor necrosis factor-a mediates apoptosis of brown adipocytes and defective brown adipocyte function in obesity. Proc Natl Acad Sci USA 2000; 97: 8033-8038.
41. Kirchgessner TG, Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. J Clin Invest 1997; 100: 2777-2782.